5.73  0.22 (3.99%)		02-11 16:00
Open: 5.545 High: 5.83 Volume: 1,018,285		Pre. Close: 5.51 Low: 5.39 Market Cap: 394(M)

Short term
Mid term
Targets	6-month :	7.28	1-year :	8.76
Resists	First :	6.23	Second :	7.5
Pivot price	5.17
Supports	First :	4.19	Second :	3.49
MAs	MA(5) :	4.93	MA(20) :	5.21
	MA(100) :	5.17	MA(250) :	2.96
MACD	MACD :	-0.2	Signal :	-0.3
%K %D	K(14,3) :	62.4	D(3) :	37.5
RSI	RSI(14): 54.6
52-week	High :	7.8	Low :	0.87

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PEPG ] has closed below upper band by 16.2%. Bollinger Bands are 21.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	5.83 - 5.85	5.85 - 5.87
Low:	5.33 - 5.36	5.36 - 5.38
Close:	5.69 - 5.73	5.73 - 5.76

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Tue, 27 Jan 2026
Levi & Korsinsky Notifies PepGen Inc. (PEPG) Investors - Lead Plaintiff Deadline on August 8, 2025 - The National Law Review

Wed, 10 Dec 2025
How Much Upside is Left in PepGen (PEPG)? Wall Street Analysts Think 75.44% - Yahoo Finance

Tue, 09 Dec 2025
PepGen Inc. Appoints New Chief Business Officer - The Globe and Mail

Mon, 08 Dec 2025
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer - Business Wire

Sun, 16 Nov 2025
PepGen (PEPG) Price Target Increased by 17.65% to 10.20 - Nasdaq

Wed, 12 Nov 2025
PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	69 (M)
Shares Float	40 (M)
Held by Insiders	0.1 (%)
Held by Institutions	93.3 (%)
Shares Short	2,580 (K)
Shares Short P.Month	2,390 (K)

EPS	-2.82
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.36
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-34.1 %
Return on Equity (ttm)	-62.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.41
Qtrly Earnings Growth	0 %
Operating Cash Flow	-85 (M)
Levered Free Cash Flow	-52 (M)

PE Ratio	-2.04
PEG Ratio	0
Price to Book value	2.41
Price to Sales	0
Price to Cash Flow	-4.62

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.